All four of these companies just reported quarterly results that beat expectations, yet they are getting far less attention than the ongoing AI debate. Shopify posted a 'monster quarter,' Novo Nordisk proved its weight-loss franchise is back on track, Eli

Verdict: Wait — strong fundamentals can't mask a weak backtest and a thin edge

The idea that four blue-chip names beat earnings simultaneously is well-supported by fundamentals: LLY's revenue grew 44.7% year-over-year, SHOP posted 30.1% growth with $2.0B in free cash flow, NVO's operating margin sits in the 98th percentile at 41.3%, and DIS generated $10.1B in free cash flow. Yet the backtest undercuts the narrative — a 32.6% win rate over 43 trades means roughly two of every three signals lost money, and the strategy endured a 33.2% maximum drawdown, with exit fills approximated on daily bars that could understate real losses. NVO is the only name through the entry gate today at $47.13 versus a $47.79 band, but the nearest support at $47.00 leaves almost no room before the 2.5% stop is tested. The 24-month sub-window returned just 5.7% with a 52.9% win rate, suggesting the edge is thinning rather than strengthening. With no parameter-sensitivity recommendation established, there is no robust setup beyond the default rules. **Conviction breakdown:** Backtest evidence is weak (35) given the low hit rate and severe drawdown; fundamentals are strong (78) across all four names; risk quality is moderate (38) due to daily-bar exit fills and extreme single-name volatility; thesis support is solid (70) as the earnings beats are real; and trade readiness is low (40) since only one of four names has a confirmed entry.

Trade now

**NVO is the only name in the basket with a live entry trigger right now.** Its last close of $47.13 sits below the 20-period Bollinger Band at $47.79, and ADX (14) of 54.1 is well above the 20 threshold — both conditions for the primary entry are met. The idea's thesis argues that NVO's weight-loss franchise is back on track after recent earnings, and the strategy is designed to buy that dip mechanically. The other three names need further weakness before they become actionable. SHOP closed at $155.18, roughly $19 above its Bollinger Band at $136.13 — that is the widest gap in the basket, a "far" status. LLY at $1,216.17 is about $47 above its band at $1,169.11 ("near"), and DIS at $103.19 is $2.69 above its band at $100.50 ("near"). For context, the backtest on SHOP across a 60-month window produced 43 trades with a 32.6% win rate and a cumulative return of 76.3%, but endured a 33.2% peak-to-trough drawdown — so this strategy catches momentum from pullbacks, and you must be able to sit through deep equity dips. If you take the NVO signal today, the position sizing rule caps each name at 25% of portfolio and uses a fixed-risk approach. The hard stop is a 2.5% loss per position, and the hard take-profit is 4.9% — an effective reward-to-risk of roughly 2:1. The exit layer also includes an overbought RSI signal exit (RSI above 75), a 90-bar holding-period cap, and a Fibonacci 127.2% extension target. With NVO's RSI (14) at 50.1, none of the RSI-based exits are close to triggering. "Wait" means exactly this: set price alerts on LLY at $1,169, DIS at $100.50, and SHOP at $136.13. Do not chase them at current levels. The strategy wants price to breach the lower Bollinger Band; until it does, those names are not in their entry zone.

Four earnings beats the market isn't pricing — and the fundamentals back them

The idea's core claim — that four companies across distinct sectors all beat expectations simultaneously, signaling the broader economy is still spending — has genuine fundamental support. Shopify posted 30.1% revenue growth year-over-year, reaching $11.6 billion, and per the Yahoo Finance piece, delivered a 'monster quarter.' Its operating margin reached 12.7%, placing it in the 83rd percentile among Information Technology peers, a meaningful improvement from negative operating margins as recently as 2023. Free cash flow of $2.0 billion puts SHOP in the 98th percentile for its sector. The growth-at-scale story is real. Eli Lilly is arguably the strongest fundamental anchor in the basket. Revenue grew 44.7% year-over-year to $65.2 billion, with a gross margin of 83.0% (79th percentile in Health Care) and a return on equity of 77.8%, placing it in the 90th percentile across nearly 1,000 health-care peers. Per Barron's, Lilly turned in 'nearly flawless earnings,' and the numbers bear that out — diluted EPS nearly doubled at 96.0% growth. Even with debt-to-equity at 1.54, the cash generation and ROE profile justify leverage at this growth rate. Novo Nordisk, per Barron's, is 'exiting a rough patch' with earnings that prove its weight-loss franchise is back on track. Revenue of $309 billion…

Scores

• Conviction score breakdown: 52
• Thesis support: 70
• Trade readiness: 40
• Risk quality: 38
• Backtest evidence: 35
• Fundamentals trend: 78

Watch items

• NVO — Price vs Bollinger (20)
• DIS — Price vs Bollinger (20)
• LLY — Price vs Bollinger (20)
• SHOP — Price vs Bollinger (20)
• SHOP — RSI (14)
• NVO — RSI (14)
• DIS — Price
• DIS — ADX (14) above 20